Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Shares Gap Down on Disappointing Earnings

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)’s stock price gapped down before the market opened on Tuesday following a dissappointing earnings announcement. The stock had previously closed at $47.39, but opened at $42.75. Kiniksa Pharmaceuticals International shares last traded at $45.3940, with a volume of 187,028 shares trading hands.

The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by ($0.20). The firm had revenue of $202.13 million during the quarter, compared to analyst estimates of $200.86 million. Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. Kiniksa Pharmaceuticals International’s revenue was up 65.0% on a year-over-year basis. During the same period in the previous year, the company earned ($0.12) earnings per share.

Key Stories Impacting Kiniksa Pharmaceuticals International

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Strong ARCALYST sales and big top-line growth — Q4 ARCALYST net product revenue was $202.1M and full-year 2025 ARCALYST sales were $677.6M; company revenue was up ~65% year-over-year, supporting commercial momentum. Kiniksa Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: 2026 revenue guidance raised and roughly in line with Street — company expects ARCALYST 2026 net product revenue of $900–$920M, which is around analyst consensus, giving investors a clearer view of next-year top-line potential. Kiniksa Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Cash position strengthened — year-end cash increased by $170.4M to $414.1M, improving the company’s financial flexibility for commercialization and trials. Kiniksa Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Pipeline milestones on the calendar — KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 and a KPL-1161 Phase 1 start planned by end-2026, which could drive future upside if data are positive. Kiniksa Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Revenue slightly beat estimates — Q4 revenue of $202.13M modestly exceeded consensus (~$200.9M), a technical positive but less market-moving than the EPS result. MarketBeat Q4 Results Summary
• Neutral Sentiment: Higher options activity noted — media flagged unusual options volume ahead of/around the print, which can amplify intraday moves but is not a fundamental change. Do options traders know something about KNSA stock we don’t?
• Neutral Sentiment: Call materials and transcript available — management commentary (see earnings call/transcript) will be the next focus for investors parsing growth drivers and margin outlook. KNSA Q4 2025 Earnings Call Transcript
• Negative Sentiment: EPS missed expectations — Kiniksa reported $0.17 EPS versus consensus estimates in the $0.29–$0.37 range, a clear near-term disappointment that likely pressured the share price. KNSA Misses Q4 Earnings Estimates (Zacks)
• Negative Sentiment: EPS guidance ambiguity — public materials emphasized 2026 revenue but provided little clarity on FY2026 EPS, leaving earnings visibility limited and increasing near-term uncertainty. Kiniksa Reports Fourth Quarter and Full Year 2025 Financial Results
• Negative Sentiment: Street still expects negative FY EPS — analysts collectively forecast losses for the year (consensus ~ -$0.55), which keeps valuation sensitive to execution and drug pricing trends.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, January 22nd. The Goldman Sachs Group upped their target price on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Canaccord Genuity Group started coverage on Kiniksa Pharmaceuticals International in a research report on Thursday, February 19th. They set a “buy” rating and a $62.00 price target for the company. Wedbush boosted their price target on Kiniksa Pharmaceuticals International from $48.00 to $50.00 and gave the company an “outperform” rating in a report on Tuesday, January 13th. Finally, Zacks Research cut shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 13th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Kiniksa Pharmaceuticals International presently has a consensus rating of “Moderate Buy” and an average price target of $53.71.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In related news, Director Barry D. Quart sold 20,129 shares of the business’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $41.51, for a total transaction of $835,554.79. Following the transaction, the director directly owned 12,546 shares in the company, valued at approximately $520,784.46. The trade was a 61.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Eben Tessari sold 12,048 shares of the company’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $41.56, for a total transaction of $500,714.88. Following the sale, the chief operating officer directly owned 16,666 shares of the company’s stock, valued at approximately $692,638.96. This represents a 41.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 123,623 shares of company stock worth $5,236,389. Corporate insiders own 53.48% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. USA Financial Formulas acquired a new stake in shares of Kiniksa Pharmaceuticals International in the third quarter valued at approximately $32,000. Smartleaf Asset Management LLC purchased a new stake in Kiniksa Pharmaceuticals International in the 4th quarter valued at $36,000. EverSource Wealth Advisors LLC increased its stake in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after acquiring an additional 532 shares during the last quarter. Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Kiniksa Pharmaceuticals International during the 4th quarter worth $41,000. Finally, CIBC Private Wealth Group LLC acquired a new position in shares of Kiniksa Pharmaceuticals International during the 4th quarter valued at about $41,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Stock Performance

The firm’s 50-day moving average price is $42.87 and its two-hundred day moving average price is $39.64. The stock has a market cap of $3.30 billion, a price-to-earnings ratio of 96.67 and a beta of 0.06.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.